Novel approaches to three drug antiretroviral therapy for HIV infection in 1997

Robert Leo Murphy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Study results currently support the simultaneous use of three antiretroviral agents including two nucleoside reverse transcriptase inhibitors and a protease inhibitor for the treatment of human immunodeficiency (HIV) infection. Such regimens have been recommended by the USA panel of the International AIDS Society for all patients considering treatment, and similar recommendations are being proposed by other organisations as well. This paper reviews the currently recommended triple therapy regimens, as well as novel triple therapy regimens using didanosine (2',3'-dideoxyinosine; ddI] plus stavudine (2',3'-didehydro-2',3'- dideoxythymidine; d4T).

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalAntiviral Therapy
Volume2
Issue numberSUPPL.3
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Novel approaches to three drug antiretroviral therapy for HIV infection in 1997'. Together they form a unique fingerprint.

Cite this